Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 3/20 | 0.47 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | LIPE | Q05469 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.37 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MLYCD | O95822 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7458789 | 0.88 | MAPT (0.45) | MAPTLIPEALDH1A1HTTPOLB | |
| SCHEMBL7462058 | 0.87 | LIPE (0.46) | MAPTLIPEALDH1A1HTTLMNA | |
| SCHEMBL6420779 | 0.76 | ACHE (0.42) | MAPTALDH1A1LMNAKMT2AGPBAR1 | |
| SCHEMBL7459759 | 0.72 | GPBAR1 (0.39) | MAPTALDH1A1HTTLMNAKMT2A | |
| SCHEMBL11006983 | 0.72 | TACR1 (0.57) | TACR1P2RX1MAPTCES2 | |
| SCHEMBL9495646 | 0.72 | CES2 (0.44) | LIPEALDH1A1CES2 | |
| SCHEMBL9351813 | 0.72 | CES2 (0.44) | TACR1P2RX1MAPTALDH1A1CES2 | |
| SCHEMBL7462682 | 0.71 | HTR3E (0.48) | MAPTLIPEALDH1A1HTTKMT2A | |
| SCHEMBL15397669 | 0.71 | TACR1 (0.59) | TACR1P2RX1MAPTCES2 | |
| SCHEMBL12435510 | 0.70 | TACR1 (0.54) | TACR1P2RX1MAPTMLYCDCES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020188122-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2002-12-12 | — | — | US | claimed |
| EP-1227091-A2 | Formamide intermediates for the preparation of tri-substituted imidazole compounds with multiple therapeutic properties | SMITHKLINE BEECHAM CORPORATION (US) | 2002-07-31 | — | — | EP | claimed |
| EP-1227092-A2 | Isonitrile intermediates for the preparation of tri-substituted imidazole compounds with multiple therapeutic properties | SmithKline Beecham Corporation (US) | 2002-07-31 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188122-A1 | Novel compounds | IL2, IFNG, IL1RN | TACR1 2721/4885P2RX1 2287/4885MAPT 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.